The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.
 
Howard I. Scher
Leadership - Asterias Biotherapeutics
Stock and Other Ownership Interests - Asterias Biotherapeutics
Consulting or Advisory Role - Ambry Genetics/Konica Minolta; Janssen; Janssen Research & Development; OncLive Insights; Physicans' Education Resource; Sanofi; WIRB-Copernicus Group
Research Funding - Illumina (Inst); Innocrin Pharma (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Asterias Biotherapeutics; OncLive Insights; Physicans' Education Resource; Sanofi; WIRB-Copernicus Group
 
Robert Thomas Mccormack
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Arturo Molina
Employment - Sutter Medical Group; Sutter Medical Group
Leadership - Sutter Medical Group; Sutter Medical Group
Stock and Other Ownership Interests - Sutter Medical Group; Sutter Medical Group
 
Matthew Raymond Smith
Consulting or Advisory Role - Amgen; Bayer; Janssen Oncology; Pfizer
Research Funding - Bayer (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst)
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Incyte; Pfizer
Research Funding - BioClin Therapeutics (Inst); Genentech (Inst); Janssen Oncology (Inst); Merck (Inst); Seagen (Inst)
 
Fred Saad
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen Oncology (Inst); Sanofi (Inst)
 
Ronald De Wit
Honoraria - Bayer; Janssen; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
 
Karim Fizazi
Honoraria - Astellas Pharma; Janssen; Merck; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Amgen; Janssen
 
Dana T. Aftab
Employment - Exelixis
Leadership - Exelixis
Stock and Other Ownership Interests - Exelixis
Patents, Royalties, Other Intellectual Property - Cabozantinib (Inst)
 
Ana Limon
Employment - Celgene (I); Takeda; Tango Therapeutics (I)
Stock and Other Ownership Interests - Celgene (I); Takeda; Tango Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Drug Discovery Compounds (I)
 
Martin Fleisher
No Relationships to Disclose
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Gary J. Kelloff
No Relationships to Disclose
 
Glenn Heller
Research Funding - Janssen Diagnostics